The prevalence and prophylaxis of gout in England

doi:10.1016/0895-4356(94)00244-K

Journal of Clinical Epidemiology

Volume 48, Issue 9, September 1995, Pages 1153-1158

https://doi.org/10.1016/0895-4356(94)00244-K Get rights and content

Abstract

The prevalence of gout in England was reported as having nearly doubled in the 1970s to about 3 per 1000, and it is possible that it has continued to increase. There may also have been some change in the level of prophylactic therapy compared with the 44.8% recorded in 1979. In this study, data were provided from their morbidity registers by 40 volunteer practices with a combined population of over 300,000 patients. Analyses of prevalence by age and sex, and of the extent of prophylaxis were made. The male: female ratio and the increase with age found were in line with earlier work, but overall prevalence was much higher at almost 10 per 1000. There was considerable inter-practice variation: 20% of this could be accounted for by the age and sex structure of the practice populations, but neither economic status nor broad geographical factors appeared to be significant, and it did not appear to be due to variation between practices in the level of special interest in gout. Prophylactic therapy—almost entirely allopurinol—was being prescribed for 48% of the sufferers; though practices varied widely in their propensity to give it, as a group the amount of allopurinol they used was close to the national average. The increase found in the prevalence of gout may be related to an increase in obesity in the population.

References (18)

WJC Currie
Prevalence and incidence of the diagnosis of gout in Great Britain
Ann Rheum Dis
(1979)
OJ Stewart et al.
Gout
Br J Rheumat
(1990)
Royal College of General Practitioners, Office of Population Censuses and Surveys, Department of Health and Social Security
Royal College of General Practitioners, Office of Population Censuses and Surveys, Department of Health and Social Security
WJC Currie
The gout patient in general practice
Rheumat Rehab
(1978)
JH Kellgren
The epidemiology of rheumatic diseases
Ann Rheum Dis
(1964)
JS Lawrence
Heritable disorders of connective tissue
JB Wyngaarden et al.
GAW Lennane et al.
Gout in the Maori
Ann Rheum Dis
(1960)

There are more references available in the full text version of this article.

Cited by (126)

Health-related quality of life in gout in primary care: Baseline findings from a cohort study
2018, Seminars in Arthritis and Rheumatism
To examine gout-related, comorbid, and sociodemographic characteristics associated with generic and disease-specific health-related quality of life (HRQOL) in gout.
Adults with gout from 20 general practices were mailed a questionnaire containing the Health Assessment Questionnaire-Disability Index (HAQ-DI), Short-Form-36 Physical Function subscale (PF-10), Gout Impact Scale (GIS), and questions about gout-specific, comorbid and sociodemographic characteristics. Variables associated with HRQOL were examined using multivariable linear regression models.
A total of 1184 completed questionnaires were received (response 65.9%). Worse generic and gout-specific HRQOL was associated with frequent gout attacks (≥5 attacks PF-10 β = −4.90, HAQ-DI β = 0.14, GIS subscales β = 8.94, 33.26), current attack (HAQ-DI β = 0.15, GIS β = −1.94, 18.89), oligo/polyarticular attacks (HAQ-DI β = 0.11, GIS β = 0.78, 7.86), body pain (PF-10 β = −10.68, HAQ-DI β = 0.29, GIS β = 2.61, 11.89), anxiety (PF-10 β = −1.81, HAQ-DI β = 0.06, GIS β = 0.38, 1.70), depression (PF-10 β = −1.98, HAQ-DI β = 0.06, GIS 0.42, 1.47) and alcohol non-consumption (PF-10 β = −16.10, HAQ-DI β = 0.45). Gout-specific HRQOL was better in Caucasians than non-Caucasians (GIS β = −13.05, −13.48). Poorer generic HRQOL was associated with diabetes mellitus (PF-10 β = −4.33, HAQ-DI β = 0.14), stroke (PF-10 β = −12.21, HAQ-DI β = 0.37), renal failure (PF-10 β = −9.43, HAQ-DI β = 0.21), myocardial infarction (HAQ-DI β = 0.17), female gender (PF-10 β = −17.26, HAQ-DI β = 0.43), deprivation (PF-10 β = −7.80, HAQ-DI β = 0.19), and body mass index ≥35 kg/m² (PF-10 β = −6.10, HAQ-DI β = 0.21).
HRQOL in gout is impaired by gout-specific, comorbid, and sociodemographic characteristics, highlighting the importance of comorbidity screening and early urate-lowering therapy. Both gout-specific and generic questionnaires identify the impact of disease-specific features on HRQOL but studies focusing on comorbidity should include generic instruments.
Gout
2017, The Heart in Rheumatic, Autoimmune and Inflammatory Diseases: Pathophysiology, Clinical Aspects and Therapeutic Approaches
Gout is the most common cause of inflammatory arthritis. It is caused by the deposition of urate crystals in synovial fluids and surrounding tissues, which may lead to inflammation. For the past few decades, increasing evidence has shown that there is a relationship between serum uric acid, gout, and cardiovascular diseases. However, it is still controversial whether this association is a causal one or should be attributed to the comorbidities and risk factors those diseases share. Gout and uric acid could be seen as metabolic markers of cardiovascular diseases. Another unsolved question pertains to the potential impact of gout treatment on cardiovascular risk factors and comorbidities. This chapter will review the current evidence and will try to answer these important questions.
The rising prevalence and incidence of gout in British Columbia, Canada: Population-based trends from 2000 to 2012
2017, Seminars in Arthritis and Rheumatism
Gout is increasingly recognized as the most common form of inflammatory arthritis worldwide; however, no Canadian data on the disease burden of gout are available. We estimated the prevalence, incidence, prescription patterns, and comorbidity burden of gout in an entire Canadian province [British Columbia (BC)] over the last decade.
We utilized PopulationData BC, a province-wide database, to estimate temporal trends in the prevalence and incidence of gout from 2000 to 2012, as well as according to age category. Annual estimates were age–sex-standardized using 2012 as the reference. We also examined annual trends in prescription patterns of common gout medications and assessed the comorbidity burden among gout patients in 2012.
The 2012 prevalence of gout was 3.8% among the overall population, and the incidence rate was 2.9 per 1000 person-years. Both gout prevalence and incidence increased substantially over the study period. This burden additionally increased according to age category, affecting over 8% of those ages 60–69 years in 2012. Approximately 22% of gout patients received a prescription for urate-lowering therapy (ULT), which remained stable over the study period, while colchicine and oral glucocorticoid use both increased modestly. By 2012, 72%, 52%, and 18% of prevalent gout patients had been diagnosed with hypertension, hyperlipidemia, and diabetes, respectively.
The burden of gout in BC, Canada, is substantial, and both the prevalence and incidence have increased over the past decade, while prescription of ULT remains low. These data support the need to improve gout prevention and care.
The Human and Economic Burden of Difficult-to-Treat Gouty Arthritis
2015, Joint Bone Spine
Gouty arthritis, one of the most painful and common forms of adult arthritis, is caused by monosodium urate crystal deposits in joints, most often in the lower extremities. Crystals trigger an inflammatory response leading to acute flares characterized by a rapid onset of pain, warmth, swelling, and redness in involved joints. Over time, continued monosodium urate crystal deposits and inflammation can lead to chronic tophaceous gout that result in bone erosion, progressing to joint destruction and significant disability. The goal of therapy in an acute gout flare is prompt and safe termination of pain and inflammation. Acute gouty arthritis is usually treated with nonsteroidal anti-inflammatory drugs, colchicine, or corticosteroids. However, for a growing number of patients, current standard treatments are ineffective or are contraindicated, largely due to the presence of comorbidities. Gouty arthritis can have a major negative impact of health-related quality of life, especially in patients with difficult-to-treat disease, as revealed by recent studies comparing health-related quality of life with that of the general population. Additionally, gouty arthritis also constitutes an important economic burden through absence from work and medical costs. This burden is even greater in patients with difficult-to-treat disease.
Epidemiology of gout
2015, Rheumatology: Sixth Edition
Joint Clinical Consensus Statement of the American College of Foot and Ankle Surgeons<sup>®</sup> and the American Association of Nurse Practitioners™: Etiology, Diagnosis, and Treatment Consensus for Gouty Arthritis of the Foot and Ankle
2018, Journal for Nurse Practitioners
Gout is a condition that commonly affects the foot and ankle, and practitioners who treat these structures should be aware of the methods used to diagnose and treat this form of arthritis. Practitioners also need to recognize extra-articular manifestations of the disease. Although the acutely red, hot, swollen joint is a common presentation, chronic tophaceous gout can be associated with pain, nodule formation, and cutaneous compromise. Since the underlying causes that lead to excessive monosodium urate deposition may be treatable, early and accurate diagnosis has been very beneficial and may even prevent articular degeneration. In this clinical consensus statement, gout as it affects the foot and ankle is discussed.

View all citing articles on Scopus

View full text

Original articleThe prevalence and prophylaxis of gout in England

Abstract

Prevalence and incidence of the diagnosis of gout in Great Britain

Ann Rheum Dis

Gout

Br J Rheumat

The gout patient in general practice

Rheumat Rehab

The epidemiology of rheumatic diseases

Ann Rheum Dis

Heritable disorders of connective tissue

Gout in the Maori

Ann Rheum Dis

Original article
The prevalence and prophylaxis of gout in England